Page last updated: 2024-08-24

tasosartan and losartan

tasosartan has been researched along with losartan in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (37.50)18.2507
2000's1 (12.50)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Antane, M; Antane, S; Bender, R; Collini, MD; Ellingboe, JW; Hartupee, D; McCallum, J; Nguyen, TT; Park, CH; White, V1
Goldberg, MR; Greenlee, WJ; Irvin, JD; Prendergast, K; Smith, RD; Timmermans, PB; Wexler, RR1
Berellini, G; Cruciani, G; Mannhold, R1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Giridhar, R; Murumkar, P; Naik, P; Yadav, MR1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Fluharty, SJ; Hines, J; Sakai, RR1

Reviews

3 review(s) available for tasosartan and losartan

ArticleYear
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
    Journal of medicinal chemistry, 1996, Feb-02, Volume: 39, Issue:3

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Humans; Receptors, Angiotensin; Structure-Activity Relationship

1996
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
    Bioorganic & medicinal chemistry, 2010, Dec-15, Volume: 18, Issue:24

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Losartan

2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for tasosartan and losartan

ArticleYear
Pyrido[2,3-d]pyrimidine angiotensin II antagonists.
    Journal of medicinal chemistry, 1994, Feb-18, Volume: 37, Issue:4

    Topics: Animals; Blood Pressure; Liver; Male; Pressoreceptors; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tetrazoles

1994
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
    Journal of medicinal chemistry, 2005, Jun-30, Volume: 48, Issue:13

    Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Binding Sites; Biphenyl Compounds; Kinetics; Losartan; Models, Molecular; Molecular Conformation; Oxidation-Reduction; Pharmaceutical Preparations; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Structure-Activity Relationship; Tetrazoles

2005
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling.
    European journal of pharmacology, 1999, Nov-12, Volume: 384, Issue:1

    Topics: Adrenal Glands; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Binding, Competitive; Biphenyl Compounds; Cells, Cultured; Dose-Response Relationship, Drug; Iodine Radioisotopes; Irbesartan; Kidney; Liver; Losartan; Male; PC12 Cells; Pituitary Gland; Pyrimidines; Radioligand Assay; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Signal Transduction; Tetrazoles

1999